Containing the C-terminus and repeat regions of the Plasmodium falciparum circumsporozoite protein (CSP) fused to the hepatitis B surface antigen, this vaccine could provide a significant contribution to reducing the burden of malaria on African children, despite not reaching the 75% efficacy target set by WHO’s Malaria Vaccine Technology Roadmap. This evidence concerns the gene DNAJC5 and malaria.